Oxycodone Synthesis Reducing Genotoxic Impurities
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing oxycodone hydrochloride often result in high levels of the genotoxic impurity 14-hydroxycodeinone, which is difficult to remove and can contaminate the final product, posing stability and safety concerns during storage and handling.
Innovation Solution
A novel process involving the reduction of 14-hydroxycodeinone to 14-hydroxycodeine, followed by a metal-catalyzed rearrangement to form oxycodone, effectively converting diol precursors to triols that are inert and incapable of generating 14-hydroxycodeinone, thereby reducing impurity levels and stabilizing the product.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional acid-catalyzed dehydration is used to convert diols to 14-hydroxycodeinone, then the conversion efficiency is improved, but the level of genotoxic impurity 14-hydroxycodeinone increases
Solution Approach 1:
The patent converts the harmful genotoxic impurity 14-hydroxycodeinone into a beneficial intermediate by performing reductive amination to form 14-hydroxycodeine, which then serves as a precursor for oxycodone synthesis. This transforms the harmful substance into a useful component of the product pathway.
Solution Approach 2:
The patent performs preliminary purification steps including treatment with activated carbon and selective crystallization before the main synthesis steps to remove diol precursors and existing 14-hydroxycodeinone impurities. This preliminary action prevents impurity formation in subsequent steps and ensures low impurity levels in the final product.
2Manufacturing precision
If extended acid treatment is used to ensure complete conversion, then the reaction completeness is improved, but the formation of 14-hydroxycodeinone impurity increases
Solution Approach 1:
The patent performs preliminary removal of diol precursors through treatment with activated carbon and selective crystallization steps before the main synthesis. This preliminary action eliminates the substrates that would otherwise convert to impurities during extended acid treatment, allowing complete conversion without impurity formation.
Solution Approach 2:
The patent carefully controls acid concentration, temperature, and treatment time parameters to achieve complete conversion of desired substrates while minimizing impurity formation. Specific conditions are optimized to distinguish between productive conversion and side reactions leading to 14-hydroxycodeinone.
3Manufacturing precision
If multiple purification steps are added to remove 14-hydroxycodeinone, then the product purity is improved, but the process complexity increases
Solution Approach 1:
Instead of adding complex purification steps to remove 14-hydroxycodeinone, the patent converts it into 14-hydroxycodeine through reductive amination, which is then transformed into oxycodone. This eliminates the need for additional purification steps while ensuring purity, as the impurity pathway becomes the product pathway.
Solution Approach 2:
The patent uses carefully controlled pH adjustment and selective crystallization conditions to purify intermediates and final product. By optimizing these parameters, high purity is achieved through simple phase separation and filtration rather than complex multi-step purification procedures.
4Object-generated harmful factors
If rapid processing is used to prevent diol dehydration, then impurity formation is reduced, but the processing time is shortened
Solution Approach 1:
The patent performs preliminary removal of diol precursors through treatment with activated carbon and selective crystallization before the main synthesis steps. This preliminary action prevents impurity formation during subsequent processing, allowing adequate time for complete reactions without generating 14-hydroxycodeinone.
Solution Approach 2:
The patent optimizes temperature, pH, and time parameters for each step to maximize reaction efficiency while minimizing impurity formation. Conditions are specifically tuned to prevent acid-catalyzed dehydration of diols during processing, eliminating the need for rushed operations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This process significantly reduces the levels of 14-hydroxycodeinone to zero or low single-digit ppm, ensuring the production of oxycodone with minimal genotoxic impurities and enhancing the stability of the oxycodone hydrochloride salt, allowing for wider process latitude and safer handling.
Implementation Method 1
a portion of 14-hydroxycodeinone (26.0 g wet, 16.9 g dry weight, 54.0 mmol) was combined with 135 ml methylene chloride and 15 ml methanol under nitrogen in a round bottomed flask equipped with a thermometer and a gas sparging tube. The slurry was cooled to 0-5 °C in an ice bath. Sodium borohydride (2.54 g, 66.8 mmol) was added to the slurry in one portion.
Implementation Method 2
A 20 ml Schlenk flask, equipped with a gas sparging tube and gas outlet, was flushed with nitrogen and charged with methanol (10 ml). The solvent was deoxygenated by sparging nitrogen gas through it while stirring. Bis(norbornadiene)rhodium (I) tetrafluoroborate (70 mg, 0.19 mmol) and 1,4-bis(diphenylphosphino)butane (80 mg, 0.19 mmol) were added under nitrogen and the orange solution was stirred at room temperature for 30 minutes. The solution was then sparged with hydrogen gas for 30 minutes.
Implementation Method 3
The solution of the catalyst was transferred to the solution of 14-hydroxycodeine via cannula. The combined solution was heated at 50 °C for 90 minutes.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
A method of preparing oxycodone includes forming 14-hydroxycodeine by reduction of 14-hydroxycodeinone and rearrangement of the 14-hydroxycodeine to form the oxycodone. During the reduction step, the ketone group of an undesirable contaminant precursor, 8, 14-dihydroxy-7,8-dihydrocodeinone, is reduced to a hydroxyl group thus forming a triol. This triol is substantially inert with respect to reforming 14- hydroxycodeinone and can be readily separated from oxycodone.